Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Rhea-AI Summary
Silo Pharma (NASDAQ: SILO) welcomed coordinated U.S. federal actions on April 29, 2026 that accelerate psychedelic therapeutic research and regulatory clarity for PTSD and related disorders. Key developments include ARPA-H EVIDENT initial awardees (including Johns Hopkins), FDA issuance of three Commissioner’s National Priority Vouchers, an IND clearance to DemeRx NB, and a promised final guidance on psychedelic drug development to be published imminently.
Silo frames these moves as validating data-driven approaches to complex neurological and psychiatric conditions and says the federal actions could lay groundwork for new PTSD therapies.
Positive
- ARPA-H EVIDENT initial awardees announced, including Johns Hopkins
- FDA issued three Commissioner’s National Priority Vouchers to accelerate therapies
- FDA granted IND clearance to DemeRx NB for noribogaine candidate
Negative
- Final FDA guidance for psychedelic drug development is not yet published
- Priority vouchers were issued to other firms, not to Silo Pharma
Key Figures
Market Reality Check
Peers on Argus
SILO was up 1.32% while closely ranked biotech peers showed mixed moves: ARTL (-2.19%), CERO (-23.11%), ENSC (-3.06%), PLRZ (+1.6%), PMCB (+1.33%). Momentum scanner also flagged SXTP up 3.13% and ALZN down 2.73%, reinforcing a stock-specific rather than broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | AI asset acquisition | Positive | -16.9% | Acquisition of Qwikagents.ai assets and launch of AI-focused subsidiary. |
| Apr 20 | PTSD policy tailwind | Positive | +29.3% | Company positions SPC-15 to benefit from psychedelics-focused executive order. |
| Apr 06 | European patent news | Positive | +49.0% | European intent-to-grant patent for prophylactic 5‑HT4 agonist use in PTSD-like settings. |
| Feb 23 | Share repurchase plan | Positive | +24.0% | Board-authorized buyback program of up to $1,000,000 in common stock. |
| Feb 18 | Japan IP allowance | Positive | -3.2% | Notice of Allowance in Japan for SPC-15 patent expanding PTSD IP estate. |
Positive corporate and IP news has often led to strong upside moves, but there are notable instances where favorable updates were followed by declines.
Over the last few months, Silo Pharma has focused on strengthening its PTSD and CNS franchise and capital structure. On Feb 18 and Apr 6, the company secured Japanese and European IP allowances for SPC-15 and related 5‑HT4 agonist uses, with price moves of -3.17% and +49.02%. A $1,000,000 buyback authorization on Feb 23 coincided with a 24% gain. More recently, PTSD- and psychedelics-related policy news on Apr 20 drove a 29.34% rise, while the Apr 22 AI acquisition and expansion into Qwikagents saw a -16.85% reaction.
Market Pulse Summary
This announcement highlights growing federal support for psychedelic-based treatments, including IND clearance for a peer program and issuance of three Commissioner’s National Priority Vouchers, which collectively reinforce the policy backdrop for PTSD therapies. For Silo, this sits alongside recent IP wins in Japan and Europe and a history of sharp moves around PTSD-related news. Investors may watch how SPC-15 progresses toward IND interactions, how the company balances its new AI initiative with core clinical work, and any further regulatory clarity specific to psychedelic development.
Key Terms
investigational new drug (ind) regulatory
ind clearance regulatory
alcohol use disorder medical
AI-generated analysis. Not financial advice.
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today commends a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend’s executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and regulatory clarity across the sector.
The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including leading institutions such as Johns Hopkins University and other innovators focused on psychedelic science. Silo believes this funding validates its position on the growing importance of data-driven approaches to treating complex neurological and psychiatric conditions.
In parallel, the U.S. Food and Drug Administration granted investigational new drug (IND) clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, highlighting continued expansion of clinical-stage programs in the mental health space.
“We are witnessing a coordinated and accelerating shift at the federal level,” said Silo CEO Eric Weisblum. “From funding and clinical advancement to regulatory prioritization, in our opinion the foundation is being laid for a new generation of therapies that could transform how we treat PTSD and related disorders.”
The FDA issued three Commissioner’s National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a clear intent to accelerate high-impact therapies. Notably, the inclusion of a PTSD-relevant program further signals a strong institutional focus on addressing urgent unmet needs among veterans and broader patient populations. Additionally, the organization confirmed that final guidance for psychedelic drug development will be published imminently, a long-anticipated milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
